Literature DB >> 22684558

Suppression of EphB4 improves the inhibitory effect of mTOR shRNA on the biological behaviors of ovarian cancer cells by down-regulating Akt phosphorylation.

Xiangyi Ma1, Danfeng Luo1, Kezhen Li1, Ronghua Liu1, Yan Liu1, Tao Zhu1, Dongrui Deng1, Jianfeng Zhou1, Li Meng1, Shixuan Wang2, Ding Ma3.   

Abstract

The aim of the present study was to examine the effects of suppression of EphB4 and/or mTOR on the biological behaviors of ovarian cancer cells, and the potential regulatory pathways. Antisense EphB4 vectors and shRNA vectors targeting mammalian target of rapamycin (mTOR) were constructed and transfected into A2780 and SKOV3 cells (two ovarian cancer cell lines). The effects of the antisense EphB4 vectors and the shRNA vectors on the proliferation, apoptosis and invasion of ovarian cancer cells were measured, and the expression of EphB4, mTOR and Akt detected. The results showed that transfection with mTOR shRNA could inhibit growth, induce apoptosis, and reduce invasive ability of ovarian cancer cells, which was accompanied by downregulation of EphB4, mTOR and Akt. The inhibitory effects on cell growth caused by mTOR shRNA alone were weaker than those by antisense pEGFP-C1-EphB4. In the antisense pEGFP-C1-EphB4-transfected cells, it was found that EphB4 knockdown could decrease the mTOR expression and slightly reduce the Akt phosphorylation. Significant suppressive effects on cell growth were observed in cells co-transfected with antisense pEGFP-C1-EphB4 and mTOR shRNA. In co-transfection group, the expression levels of EphB4, mTOR and Akt were distinctly lower than those in other groups. It was concluded that suppression of EphB4 may inhibit the growth of ovarian cancer cells by downregulation of the PI3K/Akt/mTOR pathway, and reverse Akt phosphorylation induced by mTOR shRNA. Inhibition of EphB4 and mTOR combined may cooperatively suppress the biological behaviors of ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684558     DOI: 10.1007/s11596-012-0062-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  29 in total

Review 1.  AKT plays a central role in tumorigenesis.

Authors:  J R Testa; A Bellacosa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

2.  Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway.

Authors:  Jena J Steinle; Cynthia J Meininger; Reza Forough; Guoyao Wu; Mack H Wu; Harris J Granger
Journal:  J Biol Chem       Date:  2002-09-13       Impact factor: 5.157

3.  Induction of KLF2 by fluid shear stress requires a novel promoter element activated by a phosphatidylinositol 3-kinase-dependent chromatin-remodeling pathway.

Authors:  Justin P Huddleson; Nisar Ahmad; Seetha Srinivasan; Jerry B Lingrel
Journal:  J Biol Chem       Date:  2005-04-15       Impact factor: 5.157

4.  The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade.

Authors:  Jeffrey S Scehnet; Eric J Ley; Valery Krasnoperov; Ren Liu; Parmeet K Manchanda; Eric Sjoberg; Anna P Kostecke; Sachin Gupta; S Ram Kumar; Parkash S Gill
Journal:  Blood       Date:  2008-10-03       Impact factor: 22.113

5.  Theoretical design of antisense genes with statistically increased efficacy.

Authors:  M J Lehmann; V Patzel; G Sczakiel
Journal:  Nucleic Acids Res       Date:  2000-07-01       Impact factor: 16.971

6.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

7.  The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma.

Authors:  Qinghua Wu; Zhenhe Suo; Gunnar B Kristensen; Mark Baekelandt; Jahn M Nesland
Journal:  Gynecol Oncol       Date:  2006-02-23       Impact factor: 5.482

8.  Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma.

Authors:  Dimpy Koul; Ruijun Shen; Sherry Bergh; Xiaoyang Sheng; Shishir Shishodia; Tiffany A Lafortune; Yiling Lu; John F de Groot; Gordon B Mills; W K Alfred Yung
Journal:  Mol Cancer Ther       Date:  2006-03       Impact factor: 6.261

9.  Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.

Authors:  Nicole K Noren; Mark Lu; Andrew L Freeman; Mitchell Koolpe; Elena B Pasquale
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

10.  G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.

Authors:  Ning Gao; Daniel C Flynn; Zhuo Zhang; Xiao-Song Zhong; Valerie Walker; Ke Jian Liu; Xianglin Shi; Bing-Hua Jiang
Journal:  Am J Physiol Cell Physiol       Date:  2004-03-17       Impact factor: 4.249

View more
  3 in total

1.  TNYL peptide functional chitosan-g-stearate conjugate micelles for tumor specific targeting.

Authors:  Feng-Ying Chen; Jing-Jing Yan; Han-Xi Yi; Fu-Qiang Hu; Yong-Zhong Du; Hong Yuan; Jian You; Meng-Dan Zhao
Journal:  Int J Nanomedicine       Date:  2014-09-26

Review 2.  EphrinB2-EphB4 Signaling in Neurooncological Disease.

Authors:  Andras Piffko; Christian Uhl; Peter Vajkoczy; Marcus Czabanka; Thomas Broggini
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

Review 3.  The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient Management.

Authors:  Iason Psilopatis; Alexandros Pergaris; Kleio Vrettou; Gerasimos Tsourouflis; Stamatios Theocharis
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.